slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 47,221-47,250
Pages 3,679
Rows per page 30
Component
47,221-47,250 of 110,355
89
This slide presents qualitative interview data from a medical expert to undermine the credibility of a drug and a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
90
The slide uses direct quotes to frame the expert's skepticism regarding the company's marketing and clinical rationale.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
91
The slide uses direct quotes to highlight expert skepticism regarding safety, efficacy, and pricing.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
92
The slide presents qualitative expert feedback from a medical professional regarding drug safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
93
The slide presents qualitative feedback from a medical expert, highlighting concerns about diabetes risk and comparing the drug to the Aduhelm controversy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
94
This slide presents qualitative feedback from a medical expert, highlighting significant barriers to adoption for the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
95
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
96
The slide presents a qualitative critique from a medical professional, highlighting skepticism regarding clinical efficacy and administrative burden.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
97
The slide uses direct quotes to undermine the clinical value and safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
98
The slide uses a direct quote to highlight the physician's negative sentiment regarding the drug's value proposition versus the administrative effort required.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
100
The slide uses a direct quote to undermine the value proposition of the drug Vykat by highlighting the availability of cheaper alternatives.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
101
The slide uses direct quotes to expose contradictions in the drug's adoption and safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
102
The slide uses direct quotes to support the thesis that generic substitution is likely and that GLP-1s are effective.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
106
The red box in the image highlights the specific rows in the table that the author claims are being used to obfuscate the diabetes signal.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
107
The slide uses red boxes to draw attention to the specific data points being compared.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
108
The slide uses a screenshot of an FDA Medication Guide to contrast with the claim that DKA is missing from clinical literature.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
109
The slide uses direct quotes from medical experts to highlight a potential flaw in the company's clinical approach.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
110
The slide uses a Q&A transcript format to highlight specific patient cases that suggest a severe, long-term adverse effect.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
111
The slide uses a combination of narrative summary and a Q&A transcript excerpt to build a case against the company's clinical trial transparency.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
112
The slide uses a combination of narrative accusation and technical definitions to frame the company's data as obfuscated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
113
The slide is a reproduction of a scientific poster (Gevers et al., 2024) used as evidence for clinical trial outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
118
The slide explicitly notes the re-graphing of data from a previous page to improve numerical accuracy on the time axis and clarity of standard deviation ranges.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
119
The slide uses a red box to highlight the specific comparison between placebo and pooled data at week 13.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
120
The slide uses a red box to highlight the specific data columns that demonstrate the increase in pre-T2D and T2D patient populations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
121
The slide uses a direct quote from a medical paper to highlight a discrepancy between the company's claim and the reported data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
122
The slide uses red arrows and dots to visually demonstrate the discrepancy between cited data and the actual study graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
123
The slide uses a scatter plot with a linear regression line to refute a specific company claim regarding metabolic safety.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
124
The slide uses a red box to highlight the specific claim about 60% of participants having PD/DM at baseline.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
125
The slide uses a red oval to highlight the baseline data point and a dashed red box to represent the pre-T2D threshold range.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
126
The slide uses a direct quote from a conference abstract to highlight a discrepancy between the reported 60% figure and the author's own analysis.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit